What is SwiftSync?
Swift Sync, Inc. is at the forefront of cardiac pacing technology, offering innovative solutions centered around its patented Swift Sync Pacing Catheter. This device is engineered for temporary A-V sequential pacing, addressing critical clinical needs in operating rooms, cath labs, and emergency care settings. Its primary application is to provide safe and effective pacing post-cardiac surgery and during acute cardiac events. A key differentiator is the catheter's design, which enables secure placement without the necessity of fluoroscopic guidance, thereby mitigating risks associated with conventional pacing methods. The company targets healthcare professionals and institutions dedicated to cardiac care and surgical interventions.
How much funding has SwiftSync raised?
SwiftSync has raised a total of $3.5M across 1 funding round:
Series A
$3.5M
Series A (2021): $3.5M with participation from New World Angels
Key Investors in SwiftSync
New World Angels
New World Angels is a Florida-based group of angel investors and venture capitalists that provides seed funding and guidance to qualified early-stage companies. They aim to support entrepreneurs from diverse backgrounds and cultures, focusing on startups that can create significant market impact.
What's next for SwiftSync?
The substantial enterprise-level funding and recent strategic investment position SwiftSync for significant expansion. This capital infusion is anticipated to fuel further research and development, enhance manufacturing capabilities, and broaden the company's commercial reach. SwiftSync's focus on a critical unmet need in cardiac care, coupled with its innovative, guidance-free pacing catheter, suggests a strong trajectory for market adoption and potential for future funding rounds as it scales operations and seeks to establish a dominant presence in the cardiac device industry.
See full SwiftSync company page
